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Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited renal disorder caused by defects in the
PKD1 or PKD2 genes. ADPKD is associated with significant morbidity, and is a major underlying cause of end-stage renal
failure (ESRF). Commonly, treatment options are limited to the management of hypertension, cardiovascular risk factors,
dialysis, and transplantation when ESRF develops, although several new pharmacotherapies, including rapamycin, have
shown early promise in animal and human studies. Evidence implicates polycystin-1 (PC-1), the gene product of the PKD1
gene, in regulation of the mTOR pathway. Here we demonstrate a mechanism by which the intracellular, carboxy-terminal
tail of polycystin-1 (CP1) regulates mTOR signaling by altering the subcellular localization of the tuberous sclerosis complex
2 (TSC2) tumor suppressor, a gatekeeper for mTOR activity. Phosphorylation of TSC2 at S939 by AKT causes partitioning of
TSC2 away from the membrane, its GAP target Rheb, and its activating partner TSC1 to the cytosol via 14-3-3 protein
binding. We found that TSC2 and a C-terminal polycystin-1 peptide (CP1) directly interact and that a membrane-tethered
CP1 protects TSC2 from AKT phosphorylation at S939, retaining TSC2 at the membrane to inhibit the mTOR pathway. CP1
decreased binding of 14-3-3 proteins to TSC2 and increased the interaction between TSC2 and its activating partner TSC1.
Interestingly, while membrane tethering of CP1 was required to activate TSC2 and repress mTOR, the ability of CP1 to inhibit
mTOR signaling did not require primary cilia and was independent of AMPK activation. These data identify a unique
mechanism for modulation of TSC2 repression of mTOR signaling via membrane retention of this tumor suppressor, and
identify PC-1 as a regulator of this downstream component of the PI3K signaling cascade.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD), is
characterized by the progressive, bilateral enlargement of the
kidneys due to multiple cysts that arise from the tubular epithelial
cells of the nephron [1,2]. ADPKD has an incidence of 1 in 500 to
1 in 1000 live births and is the leading cause of end-stage renal
disease (ESRD) in the US. Although ADPKD is primarily
characterized by renal cysts, it is a systemic disorder, resulting in
epithelial cysts in multiple organs including the liver and pancreas
[3,4]. Non-cystic manifestations include hypertension, cardiac
valve abnormalities, and intracranial aneurysms [5]. Currently,
treatment for advanced ADPKD is limited to renal transplantation
or life-long hemodialysis [4]. Almost 85% of the ADPKD cases
result from mutations in the PKD1 gene on chromosome 16 that
encodes polycystin-1 [6], whereas mutations in the PKD2 gene on
chromosome 4 encoding polycystin-2, are responsible for the
remaining 15% of the cases [7,8].
Polycystin-1 (PC-1) is a large (4303 aa) integral membrane
glycoprotein (molecular mass ,460 kDa), which includes a long
(,3000 aa) N-terminal extracellular domain, 11 trans-membrane
domains and a short (,200 aa) intracellular C-terminal tail
[9,10,11,12]. PC-1 interacts via its coiled-coil domain with
polycystin-2 (PC-2), also an integral membrane protein, to act as
a calcium permeable cation channel [13]. Additionally, PC-1 has
been localized to cell-cell junctions where it modulates cell
adhesion [14,15], and at sites of cell-matrix interactions [16].
PC-1 has also been localized to the primary cilium of renal
epithelial cells, where it is thought to be involved in ciliary
mechanotransduction [17]. The C-terminal tail of PC-1 has been
reported to regulate various signaling pathways [4] including Wnt
signaling pathway [18], AP-1 transcription factor complex
signaling [19,20] and more recently, STAT6 signaling to stimulate
STAT6-dependent gene expression [21].
Accumulating evidence suggests that PC-1 might have a
functional link to the tuberous sclerosis complex 2 (TSC2) tumor
suppressor [22,23,24]. TSC2 lies at the epicenter of signal
integration in the conserved mTOR signaling cascade, which
regulates protein synthesis and cell growth [25,26]. The TSC2
gene is mutated in tuberous sclerosis complex (TSC), a systemic
disorder characterized by benign hamartomas especially of the
kidney [27]. The heterodimeric TSC2/TSC1 complex has a
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Rheb (Ras homolog enriched in brain), a major regulator of
mTORC1 (mammalian target of rapamycin complex 1) [28].
Activated mTORC1 phosphorylates and activates its down-stream
effectors ribosomal S6 kinases - S6K1 and S6K2 and eIF4E
(eukaryotic initiation factor 4E)-binding proteins, 4E-BP1 and 4E-
BP2 to stimulate protein synthesis and proliferation [29,30,31].
Studies have shown aberrant activation of mTOR in several
rodent models of polycystic kidney disease [22,32,33] and
treatment with rapamycin has been shown to alleviate cyst
enlargement in murine models [34,35,36]. Furthermore, deletion
of PKD1 and TSC2 in a contiguous gene deletion syndrome,
exhibits a severe PKD phenotype [37] further suggesting that these
two proteins may be involved in a common pathway. TSC2 is
required for the normal trafficking of PC-1 from the Golgi to the
membrane [23] and more recently, PC-1 was also shown to
interact with TSC2 [22], establishing a functional link between
these two proteins. In a recent study, PC-1 was found to inhibit
ERK-mediated phosphorylation of TSC2 at S664 [24] in both
MDCK (Madin-Darby canine kidney) and MEF (mouse embry-
onic fibroblast) cells.
We haveused a human model system to elucidate themechanism
by which PC-1 regulates the mTOR pathway and found that PC-1
modulates phoshatidylinositol 3-kinase (PI3K)/AKT signaling to
TSC2 to repress mTOR. AKT phosphorylates TSC2 at several
sites including S939, which results in the membrane partitioning of
TSC2 to the cytosol, away from its GAP target Rheb and its
activating partner TSC1 via binding of 14-3-3 proteins [38]. We
found that the C-terminal tail of human polycystin-1 (CP1) directly
interacts with TSC2 and when membrane-tethered, prevents the
inactivating phoshorylation of TSC2 at S939, thus retaining TSC2
at the membrane. This membrane retention of TSC2 enhances
TSC2 repression of mTOR signaling in human cells. Importantly,
the ability of CP1 to protect TSC2 from AKT phosphorylation and
enhance mTORrepressionoccurredintheabsence ofprimarycilia,
indicating that repression of mTOR occurs independently of CP1
localization to this organelle.
Results
Activation of mTOR Signaling in Human ADPKD
Limited evidence from recent studies has suggested a role for
loss of polycystin-1 (PC-1) in dysregulation of mTOR signaling in
human ADPKD [22,33]. We confirmed elevated mTOR signaling
in cysts of kidneys from patients with end-stage autosomal
dominant polycystic kidney disease (ES-ADPKD) relative to
normal kidneys (NHK) from unaffected individuals. Immunohis-
tochemistry from 20 ES-ADPKD kidneys and 8 NHK (in the age
range of 42–59 years) demonstrated that in many cysts, epithelial
cells lining the cysts exhibited elevated phospho-S6 staining
compared to the normal epithelial cells in unaffected NHKs
(Figure 1A). Consistent with previous reports [33], however,
immunoreactivity for phospho-S6 was heterogeneous, with both
phospho-S6 positive and phospho-S6 negative cysts observed in
affected kidneys. Immunohistochemistry data were confirmed by
western analysis of tissue from 8 ES-ADPKD kidneys and 4
NHK’s. Even though cystic kidneys from ES-ADPKD patients
contain a mixture of phospho-S6 positive and negative cysts as well
as apparently unaffected epithelial cells, and stromal cells, western
analysis was able to detect elevated levels of phospho-S6 indicative
of mTOR activation in ES-ADPKD kidneys relative to NHK
(Figure 1B) (two-tailed unpaired Student’s t-test) (p#0.02). Thus,
for at least a subpopulation of cysts, loss of PC-1 and development
of cysts correlated with activation of mTOR signaling.
The C-Terminal Tail of Polycystin-1 (CP1) Represses mTOR
Signaling
To explore a potential mechanism by which loss of PC-1 might
disrupt mTOR signaling in cystic epithelial cells, we focused on
the C-terminal, cytoplasmic tail of PC-1. The large size of PC-1
(4303 aa) limits its transfectability in transient transfection assays,
therefore the cytosolic tail of PC-1 has been used to investigate its
function [19,39,40,41,42]. As shown in Figure 2A, we utilized the
C-terminal tail of human polycystin-1 (CP1) (aa 4106 – aa 4303)
tagged with either the extracellular and transmembrane region of
CD44-, an integral membrane peptide (CD44-CP1), or a
myristoylation signal (MyrEGFP-CP1) to express membrane-
tethered CP1, or Flag (Flag-CP1) to express soluble CP1.
Expression of CD44-, MyrEGFP- and Flag-CP1 following
transient transfection into HEK-293 (human embryonic kidney)
epithelial cells or hTERT RPE-1 (human retinal pigment
epithelial) cells confirmed that high levels of both membrane
tethered and soluble CP1 were expressed from these constructs
(Figure 2B and data not shown).
The ability of CP1 to regulate mTOR signaling in human cells
was demonstrated by decreased phosphorylation of the mTOR
target S6K and its downstream effector S6 in CD44-CP1
expressing HEK-293 cells compared to vector (CD44-pcDNA3)
control cells expressing CD44 alone (Figure 2C, left). Phosphor-
ylation of S6K and S6 decreased significantly, by 90% (p#0.001,
n=5) and 49% (p#0.001, n=5), respectively as shown in
Figure 2C (right). Similar data were obtained in retinal epithelial
hTERT RPE-1 cells (data not shown), confirming the ability of
CP-1 to regulate mTOR signaling in human cells.
To investigate if CP1 was able to repress mTOR signaling
under conditions of mitogen stimulation that acutely activates
PI3K/AKT and mTOR, HEK-293 cells were starved, and then
stimulated for 1 hour with serum. As shown in Figure 2D, CD44-
CP1 significantly repressed mTOR signaling even under condi-
tions of mitogen stimulation when AKT was activated as assessed
by phospho-AKT (S473) levels. In serum-starved cells expressing
CD44-CP1, phosphorylation of S6K and S6 was significantly
lower, decreased by 69% (p#0.01, n=3) and 75% (p#0.01,
n=3), respectively over vector control (CD44-pcDNA3)
(Figure 2D, right). Upon stimulation of PI3K/AKT, CD44-CP1
repression of mTOR was even more pronounced, with 83% (S6K,
p#0.01, n=3) and 60% (S6, p#0.001, n=3) inhibition observed
(Figure 2D, right). These data indicate that CP1 is able to regulate
mTOR signaling in human epithelial cells in both the absence and
presence of a strong mitogenic signal.
Following our observation that expression of exogenous CP1
was sufficient to repress mTOR signaling, we next determined
whether endogenous PC-1 regulated mTOR signaling in human
epithelial cells, using small interfering RNA’s (siRNA) to
knockdown endogenous PC-1 in HEK-293 and hTERT RPE-1
cells. Using RT-PCR analysis to determine efficiency of PC-1
knockdown, we were able to achieve an 80% and 20% knockdown
of PC-1 mRNA in hTERT RPE-1 and HEK-293 cells,
respectively (Figure 3A). Although higher concentrations of siRNA
(.20nM) resulted in more efficient knockdowns, these were
cytotoxic, and therefore for our studies we chose the least toxic
concentration of PC-1 siRNA, which was 20 nM. Under these
conditions we found that mTOR signaling increased at least 2-fold
as assessed by phosphorylation of S6, as shown in Figure 3B, in
both HEK-293 (n=3) and hTERT RPE-1 (n=2) cells. Interest-
ingly, although PC-1 expression was reduced by only 20%
(Figure 3A), likely due to effective knockdown of PC-1 in only a
portion of HEK-293 cells, increased activation of the mTOR
pathway was readily detectable (Figure 3B) suggesting that a large
PC-1 Represses mTOR Signaling
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of PC-1.
To confirm that elevated mTOR signaling was due to loss of
PC-1 expression and not an off-target effect, CD44-CP1 was re-
expressed following endogenous PC-1 knockdown to rescue
mTOR repression. The smart-pool human PC-1 siRNA sequence
was compared to CD44-CP1 to verify lack of sequence homology
and ensure that CD44-CP1 would be expressed in conjunction
with the PC-1 knockdown (data not shown). HEK-293 cells were
transfected with PC-1 siRNA and subsequently transfected with
CD44-pcDNA3 (control) or CD44-CP1 and mTOR signaling was
assessed by western analysis for phosphorylation of S6. HEK-293
PC-1 siRNA transfected cells, co-transfected with control vector
(CD44-pcDNA3) exhibited a 2-fold elevation in mTOR signaling
relative to si-control (scrambled sequence) co-transfected with
CD44-pcDNA3 (Figure 3C, right). However, knocking down
endogenous PC-1 and expressing CD44-CP1 abrogated the effect
of PC-1 siRNA on mTOR signaling, decreasing dramatically
phosphorylation of S6 to basal levels (Figure 3C). Thus, PC-1, and
likely its cytoplasmic tail, modulates mTOR signaling in vitro,
consistent with in vivo data demonstrating mTOR activation in
cysts of ADPKD patients.
CP1 Repression of mTOR Requires TSC2, but Not Primary
Cilia or AMPK
PC-1 is localized to the primary cilia and is implicated in flow-
induced mechanotransduction, and mutations in PC-1 are linked
to the ciliary defects associated with ADPKD [17]. However,
HEK-293 cells, which showed inhibition of mTOR signaling in
response to expression of CD44-CP1 (Figure 2C and 2D), were
non-ciliated (#2%), suggesting that repression of mTOR signaling
was a cilia-independent function of CP1. Similarly, inhibition of
mTOR signaling observed in hTERT RPE-1 cells, occurred
under non-ciliated conditions when#5% of cells were ciliated, as
confirmed by staining with cilia-specific anti-acetylated alpha-
tubulin (Figure S1). Thus, the inhibition of the mTOR signaling
cascade by CP1 did not require primary cilia, and occurs via cilia-
independent pathway(s).
TSC2 is an important gatekeeper of mTOR activity, negatively
regulating mTOR signaling [28], prompting us to examine TSC2
as a possible mediator of PC-1 regulation of mTOR. As shown in
Figure 4A, in HEK-293 cells transfected with TSC2 siRNA,
endogenous TSC2 levels were decreased by more than 80%
compared to cells transfected with scrambled siRNA, and was
associated with increased mTOR signaling (Figure 4A, compare
Figure 1. Dysregulation of mTOR in human ADPKD patients. A. Normal human kidney (NHK) and ES-ADPKD kidney tissues were analyzed by
immunohistochemistry using anti-phospho-S6 antibody (stained red). The sections were visualized using Differential Interference Contrast (DIC)
microscopy. Representative images at 10x magnification are shown. B. Western blot analysis of tissue lysates from 4 NHK and 8 ES-ADPKD kidneys,
immunoblotted with anti-phospho-S6 antibody (left). The autoradiographs were quantified and plotted as a ratio of phosphorylated S6 to total S6
(right). A statistically significant (p#0.05) increase in phosphorylation of S6 was observed in ES-ADPKD kidneys compared to the NHKs.
doi:10.1371/journal.pone.0009239.g001
PC-1 Represses mTOR Signaling
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9239Figure 2. The C-terminal tail of human polycystin-1 (CP1) represses mTOR signaling. A. Schematic of the constructs used in the study. CP1
(aa 4106 – aa 4303) was tagged with either membrane-bound CD44, myristolylated EGFP or soluble Flag tag. B. Expression of the tagged-CP1
constructs transfected into HEK-293 cells was determined by immunoblotting using E1/2, anti-GFP and anti-Flag antibodies. C. Protein lysates
generated from HEK-293 cells (n=5) expressing CD44-pcDNA3 (vector control) or CD44-CP1 were analyzed using the indicated antibodies (left). The
autoradiographs were quantified and plotted as a ratio of phospho- to total protein (S6K and S6), where the vector control (CD44-pcDNA3, black
bars) and CD44-CP1 (gray bars) were normalized to 100. D. HEK-293 cells were transfected with the vector control (CD44-pcDNA3) or CD44-CP1 and
treated as indicated (n=3). Protein lysates generated from these cells were analyzed by immunoblotting using the indicated antibodies (left). The
graphs denote the ratio of phospho- to total protein (S6K and S6) (right) where the vector control (CD44-pcDNA3, black bars) and CD44-CP1 (gray
bars) ratios were normalized to 100. All blots shown are indicative of a single representative experiment and an * denotes a statistically significant
difference (p#0.05) between vector control (CD44-pcDNA3) and CD44-CP1.
doi:10.1371/journal.pone.0009239.g002
PC-1 Represses mTOR Signaling
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9239Figure 3. Polycystin-1 knockdown results in the activation of mTOR signaling in vitro.A .RT-PCR analysis of mRNA collected from hTERT
RPE-1 and HEK-293 cells expressing human PC-1 siRNA (20 nM). The relative expression of PC-1 is shown in the presence of scrambled (control, black
bars) and human PC-1 (gray bars) siRNA, normalized to 1. All RT-PCR reactions were performed in triplicate. B. Cell lysates collected from HEK-293 and
hTERT RPE-1 cells 48 hours following transfection of scrambled and PC-1 siRNA were examined by immunoblotting using the specified antibodies
(left). The blots shown indicate a single representative experiment. The graphs (right) indicate the ratio of phospho- to total S6 where the scrambled
(black bars) and PC-1 siRNA (gray bars) ratios were normalized to 1. C. Protein lysates from HEK-293 and hTERT RPE-1 cells, transfected with control or
human PC-1 siRNA and co-expressing CD44-pcDNA3 (vector control) or CD44-CP1, were analyzed by immunoblotting using the indicated antibodies
(left). The western blots are representative of two independent experiments. The autoradiographs were quantified and plotted (right) as a ratio of
phospho- to total S6. The control siRNA (with CD44-pcDNA3) is depicted as a black bar and PC-1 siRNA with either CD44-pcDNA3 or CD44-CP1 is
shown as gray bars.
doi:10.1371/journal.pone.0009239.g003
PC-1 Represses mTOR Signaling
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9239Figure 4. CP1 inhibits mTOR via a TSC2-dependent mechanism, distinct from AMPK activation of TSC2. A. HEK-293 cells transfected
with scrambled or TSC2 siRNA, co-expressing CD44-pcDNA3 or CD44-CP1 were used to generate protein lysates that were analyzed by
immunoblotting using the indicated antibodies. Blots represent a single experiment (n=3) and the graph is a ratio of phospho- to total protein. The
ratios for CD44-pcDNA3 (vector control, black bars) and CD44-CP1 (gray bars) were normalized to 1 as shown. B. Protein lysates generated from HEK-
293 cells expressing CD44-pcDNA3 (control) or CD44-CP1, treated with 0.4 mM H2O2 were analyzed by immunoblotting with the indicated
antibodies. The autoradiographs were quantified and plotted as a ratio of phospho-S6 to total S6 for the conditions indicated. Representative blots
for a single experiment are shown (n=5). The * denotes a statistically significant difference between the vector control (CD44-pcDNA3, black bars)
and CD44-CP1 (gray bars) (p#0.05).
doi:10.1371/journal.pone.0009239.g004
PC-1 Represses mTOR Signaling
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CD44-CP1, mTOR was repressed (Figure 4A, lane 2). However,
in cells depleted of TSC2 (TSC2 knockdown cells), CD44-CP1
was unable to repress mTOR signaling (Figure 4A, lane 4),
indicating that CP1 regulation of mTOR was TSC2-dependent.
TSC2 is itself regulated by several signaling pathways that
regulate mTOR, including the energy sensing AMP-activated
protein kinase (AMPK) pathway. AMPK activates the tumor
suppressor function of TSC2, leading us to investigate whether
AMPK was potentially mediating PC-1 activation of TSC2.
However, AMPK was not activated in cells expressing CD44-CP1
under conditions where CP1 repressed mTOR signaling
(Figure 4B). Furthermore, mTOR signaling could be further
repressed by CP1 under conditions in which AMPK was activated
and mTOR was repressed by TSC2. HEK-293 cells expressing
either control (CD44-pcDNA3) or CD44-CP1, were treated with
0.4 mM H2O2 to activate AMPK [43], confirmed by immuno-
blotting using a phospho-specific AMPK (T172) antibody as
shown in Figure 4B (left). In cells with activated AMPK, CD44-
CP1 further augmented the repression of mTOR when compared
to vector control (CD44-pcDNA3). On average a significant
decrease was observed in the ratio of phospho-S6 to total S6 in
non-treated cells (cells grown in normal growth media) expressing
CD44-CP1 compared to the control (p#0.01, n=5) (Figure 4B,
right) as well as cells treated with H2O2 (p#0.01, n=5). These
data indicate that CD44-CP1 repression of mTOR does not
require AMPK activation of the tumor suppressor function of
TSC2, and that CP1 can augment activation of TSC2 beyond that
achieved by AMPK activation.
CP1 Protects TSC2 from Inactivation by AKT
TSC2 regulation of mTOR requires membrane localization of
this tumor suppressor [38], where it co-localizes with its GAP
target Rheb and its activation partner TSC1. To determine if
membrane localization of CP1 impacted its ability to activate
TSC2, we compared the ability of membrane-tethered (CD44-
CP1) and soluble (Flag-CP1) CP1 to repress mTOR signaling. In
the absence of serum, mTOR was repressed by membrane-
tethered CD44-CP1, as indicated by the significantly decreased
phosphorylation of S6K and S6 (Figure 5) by 70% (p#0.05, n=3)
and 76% (p#0.05, n=3) respectively, when compared to the
control (CD44-pcDNA3). The ability of membrane-localized CP1
to repress mTOR was confirmed using myristoylated-EGFP-CP1
(myrEGFP-CP1), which reduced phosphorylation of S6K by more
than 50% (data not shown). In contrast, soluble CP1 exhibited no
repression of the mTOR pathway in quiescent or serum-
stimulated cells. As shown in Figure 5, rather than a decrease as
observed for membrane-tethered CP1, the ratio of phospho- to
total S6K increased almost 2-fold, in quiescent and serum-
stimulated cells expressing Flag-CP1 compared to the control
(Flag-pCMV) (Figure 5, right). Interestingly, in serum-starved cells,
expression of soluble CP1 actually increased mTOR signaling,
suggesting that CP1 that could not localize to the membrane
inhibited the ability of TSC2 to repress mTOR. Thus, CP1
functionality (i.e. repression of mTOR) required its membrane
localization.
As shown in Figure 2C, CP-1 was able to repress mTOR even
under conditions of mitogen stimulation when AKT is activated.
In response to mitogenic stimulation, AKT phosphorylates TSC2
on multiple residues, including S939, which causes TSC2 to be
partitioned away from the membrane by 14-3-3 proteins, thereby
relieving the inhibitory effect of TSC2 on Rheb and mTOR [38].
Concordant with mTOR repression, phosphorylation of TSC2 at
S939 was significantly reduced in cells expressing CD44-CP1
compared to vector control (CD44-pcDNA3) when cells were
stimulated with serum for 1 h (Figure 6A). Similarly, phosphor-
ylation of TSC2 at T1462, an AKT phosphorylation site not
involved in membrane localization of TSC2, was also decreased
(Figure 6A). Quantitation of the ratio of phospho- to total TSC2
(Figure 6A, right), indicated a similar reduction of 40% and 60%
(p#0.01) in AKT phosphorylation at S939 and T1462, respec-
tively. In contrast to the cells transfected with functional CD44-
CP1 (Figure 6B), cells expressing inactive Flag-CP1 showed no
difference in the phosphorylation of TSC2 at S939 (Figure 6B),
indicating that active, membrane-bound CP1 could protect TSC2
from its inactivating phosphorylation at this site. Decreased TSC2
phosphorylation was not due to decreased AKT activity in
response to expression of CP1, as AKT remained active, as
evidenced by continued AKT phosphorylation at S473, and
verified by sustained phosphorylation of FoxO1, a downstream
target of AKT (Figure 6B) in CD44-CP1 expressing cells.
AKT phosphorylation of TSC2 at S939 and S981 results in the
binding of 14-3-3 proteins to TSC2, leading to the partitioning of
TSC2 away from the membrane into the cytosol and inactivating
this tumor suppressor [38]. To determine if CD44-CP1 protection
of TSC2 from phosphorylation by AKT resulted in enhanced
membrane retention of TSC2, subcellular fractionation of HEK-
293 cells expressing CD44-CP1 was performed. In the presence of
CD44-CP1, enhanced membrane localization of endogenous
TSC2 was observed compared to cells expressing control CD44-
pcDNA3 (Figure 6C). In contrast, in cells expressing non-
functional Flag-CP1, less TSC2 is localized to the membrane
and the ratio of TSC2 in the membrane vs. cytosol was greatly
reduced (note overall levels of TSC2 were also reduced due to the
instability of cytosolic TSC2 [44]. Thus, CP-1 protection of TSC2
from inactivating phosphorylation by AKT correlated with
retention of TSC2 at the membrane (Figure 6C).
Interestingly, although only membrane-tethered CP1 could
repress mTOR, this was not due to an inability of Flag-CP1 to
directly interact with TSC2. As shown in Figure 7A, immunopre-
cipitation assays revealed that both membrane-bound CD44-CP1
and soluble Flag-CP1 were proficient in binding TSC2. However,
only CD44-CP1, in addition to enhancing membrane retention of
TSC2, significantly enhanced the interaction between TSC2 and
TSC1, as determined by immunoprecipitation assays where TSC1
was co-immunoprecipitated with TSC2 (Figure 7B, lanes 4 and 5)
(n=3). Similar results were obtained with the reverse immuno-
precipitation, where TSC2 was immunoprecipitated with TSC1
(Figure 7B, lanes 4 and 5). After normalization, we observed
between a 2 - 3-fold increase in interaction between TSC1 and
TSC2 in cells expressing CD44-CP1 vs. Flag-CP1 (p#0.05, n=3)
(Figure 7B, right).
Retention of TSC2 at the membrane in cells expressing
functional CD44-CP1, suggested that binding of TSC2 to 14-3-3
proteins was reduced, commensurable with decreased phosphor-
ylation at S939. This was confirmed in HEK-293 cells expressing
endogenous TSC2 and, either functional CD44-CP1 or non-
functional Flag-CP1. GST-14-3-3 affinity purification, revealed
enhanced binding of TSC2 to 14-3-3 proteins in the presence of
non-functional Flag-CP1 as compared to functional CD44-CP1 as
shown in Figure 7C. When the amount of affinity purified TSC2
was normalized to expression of endogenous TSC2, an almost 2-
fold enhanced binding of TSC2 to 14-3-3 was observed in Flag-
CP1 expressing cells relative to cells expressing CD44-CP1
(Figure 7C, right) (p#0.05, n=3). Thus, as shown in Figure 7D,
membrane-tethered CP1 enhanced TSC2 retention at the
membrane and protected this tumor suppressor from AKT
phosphorylation to enhance TSC2 repression of mTOR.
PC-1 Represses mTOR Signaling
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9239Figure 5. Membrane tethering of CP1 is required for its regulation of mTOR. HEK-293 cells were transfected with CD44-pcDNA3 (vector
control), CD44-CP1, Flag-pCMV (vector control) or Flag-CP1 and treated as indicated. Protein lysates were analyzed by immunoblotting with the
indicated antibodies (left). The graphs indicate the ratios of phospho- to total protein for the vector controls (CD44-pcDNA3 or Flag-pCMV, black bars)
and CD44-CP1 or Flag-CP1 (gray bars). Blots represent a single experiment (n=3 with CD44-tagged constructs, and n=2 with Flag-tagged constructs)
under the indicated conditions and the ratios were normalized to 100. An * denotes a statistically significant (p#0.05) difference between CD44-CP1
compared to its vector control (CD44-pcDNA3).
doi:10.1371/journal.pone.0009239.g005
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9239Figure 6. CP1 represses mTOR, by protecting TSC2 from its inactivating phosphorylation by AKT. A. Cell lysates obtained from HEK-293
cells expressing CD44-pcDNA3 (vector control) and CD44-CP1, treated with serum for 1h following serum starvation, were immunoblotted using the
indicated antibodies. Blots from a single representative experiment are shown for phosphorylation at S939 (n=4) and T1462 (n=2). The graph on the
right indicates the ratio of phospho- to total TSC2 at residues S939 and T1462. An * denotes a statistically significant difference between vector
control (CD44-pcDNA3, black bars) and CD44-CP1 (gray bars) (p#0.05). B. Cell lysates obtained from HEK-293 cells grown in normal growth media
containing 10% FBS, and expressing CD44-pcDNA3 (vector control), CD44-CP1, Flag-pCMV (vector control) or Flag-CP1 were analyzed using the
indicated antibodies. Blots from a single representative experiment are shown (n=4). The graph on the right denotes the ratio of phospho- to total
TSC2 (S939) for both CD44-tagged and Flag-tagged constructs. Black bars indicate the controls whereas the gray bars indicate either CD44-CP1 or
Flag-CP1. The * denotes a statistically significant difference between CD44-pcDNA3 (vector control) and CD44-CP1 (p#0.001). C. Subcellular
fractionation of HEK-293 cells expressing CD44-pcDNA3 (vector control), CD44-CP1, Flag-pCMV (vector control), or Flag-CP1. A representative blot
(n=3) showing the separated fractions analyzed using anti-TSC2, anti-lamin A/C (nuclear maker), anti-LDH (cytosolic marker), and anti-beta-integrin
(membrane marker). N – nuclear, C – cytosolic, M – membrane fraction.
doi:10.1371/journal.pone.0009239.g006
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PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9239Figure 7. Interaction of tuberin with hamartin and 14-3-3 in cells expressing functional and non-functional CP1. A. Lysates generated
from HEK-293 cells, expressing functional, membrane-bound CD44-CP1 and non-functional, soluble Flag-CP1, were used for immunoprecipitation
with anti-TSC2 and the immunoprecipitates further analyzed by immunoblotting with E1/2 and anti-Flag antibodies. B. Whole cell lysates from HEK-
293 cells expressing either CD44-CP1 or Flag-CP1 were used for immunoprecipitation with anti-TSC2 or anti-TSC1 antibodies, and the
immunoprecipitates analyzed by immunoblotting with anti-Flag (to detect Flag-TSC1), or anti-TSC2, respectively. Blots from a single representative
experiment are shown (n=3). The graph on the right shows the ratio of pull down to the expression of Flag-TSC1 and TSC2 as indicated.
Quantification of blots from both immunoprecipitation assays showed a statistically significant difference (*) in the interaction between TSC2 and
TSC1, in cells expressing CD44-CP1 (black bars) and Flag-CP1 (gray bars). C. Protein lysates from HEK-293 cells expressing CD44-CP1 or Flag-CP1 were
affinity purified using GST-14-3-3 or GST alone and immunoblotted with an anti-TSC2 antibody. The immunoblot for a single representative
experiment is shown (n=3). The graph on the right depicts the ratio of affinity-purified TSC2 to total endogenous TSC2 in cells expressing CD44-CP1
(black bar) or Flag-CP1 (gray bar) and the * denotes a statistically significant difference between the two. D. Model for polycystin-1 inhibition of mTOR
signaling via TSC2.
doi:10.1371/journal.pone.0009239.g007
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Accumulating evidence implicates PC-1 and TSC2 in the
mTOR pathway [22,24,33] suggesting that both PKD and TSC
may share a common pathway of renal cystogenesis. We have
demonstrated that the short intracellular C-terminal tail of
polycystin-1 (CP1) when membrane-bound, enhances TSC2-
mediated repression of mTOR signaling in human cells. CP1’s
ability to interact with and protect TSC2 from inactivating
phosphorylation by AKT retained TSC2 at the membrane, where
it was active and able to exert its tumor suppressor function to
repress mTOR. Importantly, regulation of TSC2 by CP1 appears
to be distinct from AMPK activation of TSC2, and does not
require localization of CP1 to primary cilia. Thus, we have
elucidated a mechanism by which PC-1 regulates mTOR, a
critical kinase that controls cell growth and proliferation.
Previous reports showed activation of the mTOR pathway in
human ADPKD patients by immunohistological staining using
tissue from ADPKD patients [22,33]. We have confirmed this
observation and demonstrated that knocking down endogenous
PC-1 in human epithelial cells in vitro also elevated mTOR
signaling. We observed activation of the mTOR pathway even
under conditions of a 20% knockdown (HEK-293 cells).
Importantly, a dramatic increase in the phosphorylation of S6K
and S6 detectable by western analysis under conditions where
20% of the cells have lost PC-1 is sufficiently large so as to be
detected even in this heterogeneous population. This is consistent
with clinical data, where even though cyst positivity is heteroge-
neous, positive cysts show dramatic differences in immunoreac-
tivity relative to unaffected tubules. Importantly, what remains to
be established is how heterogeneity for loss of PC-1 correlates with
the observed heterogeneity for mTOR activation, especially given
the likelihood that additional events are required for both
cystogenesis and mTOR activation observed in cystic epithelial
cells.
AKT phosphorylates TSC2 to inhibit its tumor suppressor
function and activate mTOR signaling. We propose a mechanism
by which membrane-tethered CP1 suppresses mTOR signaling by
altering the subcellular localization of TSC2 (Figure 7D). In the
presence of functional, membrane-bound PC-1/CP1 AKT
phosphorylation of TSC2 is inhibited, retention of TSC2 at the
membrane is increased, as is the interaction between TSC2 and its
activating partner TSC1 and concomitantly, binding of 14-3-3
proteins to TSC2 is decreased. The exact mechanism by which the
carboxy-terminus of PC-1 protects TSC2 from inactivating
phosphorylation by AKT will require further investigation.
However, while recent studies have emphasized the importance
of localization of PC-1 to the primary cilia [45,46], our data using
non-ciliated cells would suggest that the regulation of mTOR by
CP1 is a cilia-independent function of this cystoprotein.
These data may also go a long way toward explaining recent
observations by Distefano et al. [24], where in spite of observing
the anticipated activation of AKT on expressing full-length PC-1,
the authors failed to observe an increase in phosphorylation of
TSC2 at S939. In fact, over expressing full-length PC-1 may have
protected TSC2 from AKT phosphorylation (our data), suggesting
that as per our C-peptide, full-length PC-1 also protects TSC2,
further validating this model (Figure 7D). In addition to
demonstrating that membrane-tethered CP1 altered the subcellu-
lar localization of TSC2 to regulate mTOR signaling, our data
also revealed that the localization of CP1 was critical for its
function. Importantly, soluble CP1 (Flag-CP1) that was unable to
localize to the membrane failed to repress the mTOR pathway
and in fact activated the signaling cascade. Although functionally
deficient, this soluble CP1 was fully capable of interacting with
TSC2, suggesting that soluble CP1 could be interacting with
TSC2 in the cytosol, thereby interfering with TSC2’s ability to
localize to the membrane.
Dysregulation of the mTOR pathway has not only been
implicated in ADPKD, but in a number of other renal cystic
disorders such as ARPKD [47] and several rodent models with
mutations in other cystoprotein genes [17,48]. Although, studies
have demonstrated dysregulation of mTOR signaling associated
with pathogenesis, the exact mechanisms by which these various
cystoprotein gene products modulate this pathway are not
understood. Importantly, the PC1-TSC2 model proposed above
identifies a mechanism by which PC-1 regulates the mTOR
pathway, and provides new data for future studies aimed at
investigating the role of other cystoproteins in regulation of
mTOR signaling. Given that rapamycin – an mTOR inhibitor,
shows efficacy in several rodent models of polycystic kidney disease
[22,34,49] it would be interesting to determine if these renal
cystoproteins act at or upstream of the PC1-TSC2 node of the
pathway, implicating PC1-TSC2 as a pathogenic nexus in these
disorders. Future experiments elucidating the functionality of
TSC2 in other renal cystic disorders will be critical in answering
this question. Although promising, rapamycin has been shown to
have a variety of adverse side effects [50,51] and has yet to exhibit
dramatic efficacy as a single-agent therapeutic in cancer settings.
Additionally, relief of negative feedback to AKT induced by
mTOR inhibitors is a potential adverse consequence of treatment
with these drugs, especially in the setting of TSC2 deficiency
[52,53,54,55]. If TSC2 is at a pathogenic nexus for cystogenesis in
the setting of PKD, the potential to upregulate AKT in response to
treatment with rapalogs becomes a significant concern. Recently a
dual pan class I PI3K/mTOR catalytic small molecule inhibitor
NVP-BEZ-235 used to treat TSC2-deficient kidney tumors did not
induce the increase in phospho-AKT (S473) levels observed with
RAD001 [53], although both drugs were equally effective in
suppressing tumor growth. The identification of the role and
function of PC-1 in the mTOR pathway provides additional
targets, including AKT, whose modulation either singly, or in
combination with rapamycin, may contribute to alternative
therapeutic strategies in the treatment of ADPKD.
Materials and Methods
Cell Culture, Transfections and Treatments
HEK-293 cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). hTERT RPE-1 cells were a kind gift of Dr. Gregory Pazour
(University of Massachusetts Medical School, MA) and were
maintained in DMEM/F12 media supplemented with 10% FBS.
All transfections were performed using Lipofectamine2000
(Invitrogen) according to the manufacturers protocol. In order to
obtain the HEK-293 cells in the quiescent phase, cells were serum
starved for 16 hours in media lacking FBS, 6 hours after
transfection. The quiescent cells were stimulated with 20% serum
for an hour before harvesting. For hydrogen peroxide (H2O2)
(Sigma-Aldrich) treatments, transfected cells were grown in normal
growth media overnight (,16 hours) and treated with 0.4 mM
H2O2 for 1 hour before harvesting.
Plasmid Preparation
The extracellular region of human CD44 with its single
transmembrane domain (residues 1–289) was cloned in-frame
with the C-terminus of polycystin-1 (residues 4106–4303) in
pcDNA3 (Invitrogen) using the HindIII and ApaI sites. The
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FLAG tagged CP1 was expressed in p3xFLAG-CMV (Sigma).
Cell Lysates and Antibodies
Cell lysates from HEK-293 and hTERT RPE-1 cells were
prepared in cold 1X cell lysis buffer (20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate) containing 1X Complete prote-
ase inhibitor (Roche, Mannheim, Germany) and 1 mM Na3VO4.
The lysates were analyzed by immunoblotting with the following
antibodies: S6, phospho-S6 (S235/236), S6K, phosho-S6K
(T389), AKT, phospho-AKT (S473), phosho-TSC2 (S939 and
T1462), FoxO1 (L27), and phospho-FoxO1 (S256) (Cell Signaling
Technology), LDH (Chemicon International), EGFP (Abcam),
Flag (Sigma-Aldrich), GAPDH, lamin A/C (Santa Cruz Biotech-
nology, Inc.), TSC2 (Epitomics), beta-integrin (Clontech Labora-
tories, Inc.), TSC1 (Zymed Laboratories, Inc.). The E1/2 antibody
is a mouse monoclonal antibody specific for the extracellular
domain of CD44 and has been described previously [56].
Horseradish peroxidase (HRP)-conjugated goat anti-mouse, goat
anti-rabbit and donkey anti-goat secondary antibodies were
purchased from Santa Cruz Biotechnology, Inc.. All immunoblots
were visualized using LumiGLO
TM (KPL, Gaithersburg, MD)
substrate.
Human Tissue
All studies were conducted with specific approval of the
Institutional Review Board according to NIH guidelines (catego-
rized as exempt number 4) and in a HIPAA-compliant fashion. All
specimens used in this study were designated as ‘‘discarded’’ and
were supplied by a third party source (National Disease Research
Interchange, Philadelphia, and the Polycystic Kidney Disease
Foundation, Kansas) without identifiers.
Immunohistochemistry
Age-matched (42–59yr) normal and ADPKD kidneys, perfused
in situ and fixed at source in 4% fresh paraformaldehyde (EM
Sciences, Hatfield, PA) in phosphate buffered saline (PBS), pH 7.4,
embedded in paraffin were sectioned at 5 microns and subjected to
immunohistochemistry using anti-phospho S6 (S235/236) anti-
body (Cell Signaling) and an indirect avidin-biotin-immunoper-
oxidase technique (Vectastain Elite, Vector Laboratories). Color
development was carried out for 45 min using aminoethylcarba-
zole as substrate, generating a red reaction product. Tissue
sections were mounted with Aquamount (Polysciences) and viewed
under a Nikon Eclipse 2000 microscope equipped with Differential
Interference Contrast (DIC) optics.
siRNA Knockdown Assays and RT-PCR Analysis
Chemically synthesized siRNA SMARTpools were obtained
from Dharmacon (human TSC2, M-003029-02; human PC-1, L-
007666-00; siCONTROL, D-001210-01-05). The oligos were
resuspended in 1X buffer to a concentration of 20 mM. The stock
solutions of siRNA were diluted 1:50 (making a final siRNA
concentration of 20 nM) in 1X buffer, and DharmaFECT1
transfection reagent (Dharmacon) was diluted 1:50 in OptiMEM
medium (Invitrogen). The diluted siRNA and transfection reagent
were then incubated for 20 minutes at room temperature, prior to
transfecting the cells, in a 1:2 ratio in a total volume of 300 ml.
Knockdown efficiency was determined by RT-PCR analysis of
mRNA collected from the cells 24 hours following transfection.
mRNA was isolated from cells using the RNeasy
TM Mini Kit
(Qiagen), according to the manufacturer’s protocol. mRNA was
further purified by removal of DNA using Ambion’s RiboPure
TM
Kit (Austin, TX), according to the maufacturer’s instructions.
Following RNA extraction, cDNA was made by reverse-
transcribing 1 mg of RNA using the Invitrogen Superscript
TM
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad,
CA). Aliquots of cDNA were made for each sample and stored at -
20uC until analyzed. Real-time PCR was performed using the
7900T Fast Real-Time detection system from Applied Biosystems
(ABI, Foster City, CA). Fast Real-Time Taq-Man assays from ABI
were used to analyze gene expression of PKD1. All real-time PCR
reactions were performed by mixing Universal Fast Real-Time
Master Mix from ABI together with the gene assay mix first and
then adding 2 ml of cDNA from each sample to make up a 25 ml
volume. For an endogenous control, glyceraldehyde-3-phosphate
(GAPDH) was used, which included probe and forward and
reverse primer in a 25 ml reaction volume. The following set of
conditions were used for each real-time reaction: 95uC for 10
minutes followed by 40 cycles of 1 second at 95uC and 20 seconds
at 60uC. The real-time PCR reactions were all performed in
triplicate and were quantified using the -DDCT method, which
uses the average CT of the GAPDH subtracted from the target
gene CT to obtain the average DCT. The control siRNA was used
as a calibrator from which we subtracted individual PC-1 siRNA
DCT values to obtain the -DDCT. The fold change for the sample
was calculated in comparison to the calibrator by taking 2
2DDCT.
Subcellular Fractionation
HEK-293 cells were harvested 24 h after transfection and
washed with ice cold PBS. The cells were resuspended in hyotonic
buffer (10 mM HEPES (pH 7.2), 10 mM KCl, 1.5 mM MgCl2,
0.1 mM EGTA, 20 mM NaF, 100 mMN a 3VO4) and disrupted
using a Dounce homogenizer. Crude nuclei were pelleted by
centrifugation and the supernatant subjected to ultracentrifugation
at 29,000 rpm at 4uC for 1.5 h. This yielded the cytosolic fraction
(supernatant) and the membrane fraction (pellet). The pellet was
lysed in 1X lysis buffer and the pure membrane fraction collected
after centrifugation at 14,000 rpm for 10 min at 4uC. The crude
nuclei were resuspended in hypotonic buffer and any unbroken
cells disrupted in the Dounce homogenizer. The pellet after
centrifugation at 3000 rpm at 4uC for 5 min was washed with a
wash buffer (10 mM Tris (pH 7.4), 0.1% NP-40, 0.05% Na-
deoxycholate, 10 mM NaCl, 3 mM MgCl2) and lysed in a high
salt buffer (20 mM HEPES (pH 7.4), 0.5M NaCl, 0.5% NP-40,
1.5 mM MgCl2). The purified nuclear fraction was collected after
centrifugation at 14,000 rpm at 4uC for 10 mins. The nuclear,
cytosolic and membrane fractions were subsequently subjected to
SDS-PAGE and immunoblot analysis.
GST-14-3-3 Pulldown assays and Immunoprecipitations
GST-14-3-3 and GST (control) containing pGEX vector was
overexpressed in Escherichia coli DH5a (Invitrogen) and the fusion
proteins induced with 0.2 mM isopropyl–b-D-thiogalactopyrano-
side (IPTG). GST fusion proteins (GST alone and GST-14-3-3b)
were then batch-purified from extracts, following sonication to lyse
the cells, by binding to glutathione Sepharose 4B beads
(Amersham Pharmacia Biotech) according to the manufacturer’s
instructions. The purified fusion proteins (10 mg) bound to agarose
beads were mixed with 300-mg of protein from lysates of
transfected cells and incubated overnight at 4uC. Beads were
washed thrice in PBS containing protease inhibitors, eluted in 2x
SDS sample buffer (125 mM Tris-HCl, 20% glycerol, 4% SDS,
and 0.005% bromphenol blue), heated to 95uC, and analyzed by
immunoblotting.
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transfected HEK-293 cells were incubated with the indicated
antibodies and protein A- and protein G – Sepharose beads
(Amersham Biosciences, Piscataway, NJ) overnight at 4uC. The
immunoprecipitates were washed with a wash buffer (10 mM Tris
(pH 7.5), 1% NP-40, 1% Triton X-100, 100 mM NaCl, 50 mM
NaF, 2 mM EDTA, 1 mM PMSF and Complete protease
inhibitor (Roche, Mannheim, Germany)) and subjected to
immunoblot analysis.
Statistical Analyses
All statistical analyses were performed using the Student’s T-test
for determination of differences between the average values of
quantitation data obtained from densitometric analyses of
immunoblots. A value of p#0.05 was considered to be statistically
significant.
Supporting Information
Figure S1 Immunocytochemistry (ICC) images at 40x magnifi-
cation, showing staining for cilia using a - acetylated tubulin (cilia
marker), and DAPI (nuclear marker) in HEK-293 and hTERT
RPE-1 cells. The arrowhead indicates cells with cilia.
Found at: doi:10.1371/journal.pone.0009239.s001 (0.59 MB
PDF)
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